Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Use of Nitrous Oxide for Pain and Anxiety Management During Cervical Cerclage Removal

The goal of this clinical trial is to determine whether inhaled nitrous oxide can reduce pain and anxiety during cervical cerclage removal compared with standard care. Cervical cerclage removal is commonly performed in the outpatient setting during the third trimester of pregnancy and may be associated with discomfort and anxiety despite being a brief procedure. The study will include pregnant women aged 18 years or older undergoing elective cervical cerclage removal at 36 weeks of gestation or later. The main questions the study aims to answer are: * Does inhaled nitrous oxide reduce pain during cervical cerclage removal? * Does inhaled nitrous oxide reduce anxiety during the procedure? * Does the use of nitrous oxide improve overall patient satisfaction during cerclage removal? Researchers will compare women receiving inhaled nitrous oxide to those receiving standard care without analgesia, as routinely practiced in the participating institutions, in order to determine whether nitrous oxide improves pain control and patient experience during the procedure. Participants will: * Be randomly assigned to receive either inhaled nitrous oxide (50% nitrous oxide / 50% oxygen) or standard care without analgesic treatment during cervical cerclage removal. * Undergo the procedure according to routine clinical practice in the participating centers. * Complete questionnaires assessing pain and anxiety, including a visual analog scale (VAS) for pain and the State-Trait Anxiety Inventory (STAI). * Have routine clinical data recorded from their medical records, including maternal vital signs and any procedure-related side effects.

Participants needed: 60
Trial details
Age: 18+Biological sex: FemaleType: InterventionalSponsor: Kaplan Medical CenterUpdated: Apr 8, 2026Locations: 4
Eligibility criteria

Age ≥18 years [+3]

Triplet or higher-order pregnancy [+8]

Status: Recruiting

Prevalence of Ethnic Neutropenia and Duffy Null Phenotype in Neonates

This is a prospective observational study designed to assess the prevalence of the Duffy null phenotype (associated with ethnic neutropenia) in neonates born at Kaplan Medical Center. Blood samples will be collected from umbilical cords (non-invasively) to evaluate Duffy antigen expression. Data on ethnicity, perinatal factors, and routine blood counts at 9-12 months (when available) will also be collected to correlate phenotype with absolute neutrophil count (ANC).

Participants needed: 1,000
Trial details
Age: 1-1Biological sex: AllType: ObservationalSponsor: Kaplan Medical CenterUpdated: Apr 6, 2025Locations: 1
Eligibility criteria

Neonates born at Kaplan Medical Center between 1.9.2024 and 31.12.2025 [+2]

None

Status: Not yet recruiting

Iron Deficiency in Pediatric Celiac Disease: Diet vs. Iron Supplementation Trial

This study aims to understand how to best manage iron deficiency in children newly diagnosed with celiac disease. Many children with celiac disease have low iron levels, even if they do not have anemia. While some doctors recommend iron supplements, others believe that simply following a gluten-free diet may be enough to restore iron levels naturally. In this study, children with newly diagnosed celiac disease and low iron levels (but normal hemoglobin) will be randomly assigned to one of two groups: Gluten-Free Diet Only - No additional iron supplements Gluten-Free Diet + Iron Supplementation Researchers will compare iron store levels over one year to see if iron supplements provide any additional benefit beyond the gluten-free diet alone. The study will also track possible side effects of iron supplements, such as stomach discomfort. This study will help doctors determine the best approach to managing iron deficiency in children with celiac disease, ensuring they receive the safest and most effective treatment.

Participants needed: 150
Trial details
Age: 18-18Biological sex: AllType: InterventionalSponsor: Kaplan Medical CenterUpdated: Apr 10, 2025Locations: 5
Eligibility criteria

Children aged 18 months to 18 years [+3]

IgA deficiency preventing TTG antibody monitoring [+5]